c-LEcta’s Plug & Play enzymes outperform the competition in Pfizer study

Biocatalysis is an essential tool for the synthesis of complex organic compounds, especially due to their high stereo- and regioselectivity as well as mild reaction conditions. Furthermore, the steady progress in enzyme engineering and enzyme production helped to lower the cost contribution of enzymes tremendously, rendering their use even more attractive. To further leverage biocatalysis in industry, c-LEcta has developed Plug & Play BiocatsTM, a collection of already prequalified and engineered key enzymes for sophisticated organic syntheses. Additionally, processes for their production are already in place, hence, availability within short time lines even in industrial quantities is given.

Researchers at Pfizer now have evaluated several hundreds of ATAs and ADHs from different vendors and origins to be used in the synthesis of building blocks of a gamma secretase inhibitor with potential antitumor activity1

Among all tested transaminases (ATAs) c-LEcta’s ATA-47 turned out as the most promising candidate in the initial screening. Because of its high enantioselectivity and good activity in organic solvents this enzyme was chosen for scale-up.

Also the ADHs from c-LEcta turned out as highly suitable. Here, “on the basis of cost, availability, and performance, the c-LEcta enzymes, AHD-107L and ADH-108L, were selected for further development.”

This excellent scientific work clearly demonstrates the potential of enzymes for industrial organic syntheses and should encourage other scientists to consider biocatalysis for route scouting.

If you’d like to learn more about Plug&Play BiocatsTM, please do not hesitate to contact us via contact@c-lecta.com.

1Michael Burns, Carlos A. Martinez, Brian Vanderplas, Richard Wisdom, Shu Yu,

and Robert A. Singer (2017), Org. Process. Dev. DOI: 10.1021/acs.oprd.7b00096